vehicle

Phosphatidylcholines,soya (Soybean phosphatidylcholine) is a phosphatidylcholine from soybean used in the preparation of liposomes.

D-Lin-MC3-DMA, an ionizable cationic lipid, serves as a potent siRNA delivery vehicle.

5A2-SC8 is an ionizable cationic lipid that is an ideal vehicle for the delivery of small RNAs, interacts with negatively charged cell membranes, and can be used for gene delivery and drug delivery.

HP-β-CD (HP-β-CD) is a widely used drug delivery vehicle to improve stability and bioavailability.

Polyoxyl 10 oleyl ether is an emulsifying agent. It is used as vehicle for organic compunds in aqueous solutions.

Benz[a]anthracene is a large, polycyclic aromatic hydrocarbon (PAH) consisting of four fused benzene rings that forms primarily as a byproduct from the incomplete combustion of organic matter Benz[a]anthracene is considered a probable human carcinogen based on toxicological data; Benz[a]anthracene is found in significant sources such as tobacco and cigarette smoke, coal tar, vehicle exhaust emissions, and some cooked foods, making Benz[a]anthracene a compound of interest in researches in cancer pathogenesis.

PZ-285 is a potent anticancer agent with similar antitumor activity to the clinically active agent Dox. Pz 285 improves survival, inhibits primary tumor regrowth, and inhibits lung tumor metastasis compared to vehicle control animals.

ML 23 is a melatonin analogue in the treatment and management of Parkinson's disease. ML-23 is a potential clinical candidate for the treatment of PD, and the present study has been undertaken to determine the efficacy of ML-23 in the 1-methyl-4-phenyl, 1

Ensartinib (X-396) is a potent and orally active dual ALK/MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

The truncated glucagon-like peptides GLP-1(7-37) is naturally occurring peptide product of the preproglucagon gene that are synthesized primarily in the intestine and acts as incretin that are released from the intestine into the bloodstream in response to food and stimulate insulin secretion. GLP-1(7-37) produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in Sprague-Dawley Rats at a dosing rang of 0.5, 5, or 50 pmol/min/kg. Further, infusion of GLP-1(7-37) for 60 mins produced a small transitory increase in plasma insulin concentration in fasted rats and fed rats and a slight transitory decrease in plasma glucose concentration. Moreover, GLP-1(7-37) (5 pmol/min/kg IV) infusion for 6 h in Sprague-Dawley rats produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle[1].

KD-3010 is a peroxisome proliferator-activated receptor delta agonist potentially for the treatment of diabetes and obesity. KD-3010 dramatically ameliorates liver injury induced by carbon tetrachloride (CCl(4)) injections. Deposition of extracellular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated group. Interestingly, profibrogenic connective tissue growth factor was induced significantly by GW501516, but not by KD-3010, following CCl(4) treatment.

Cipamfylline is a xanthine, a theophylline analogue, and is a potent and selective inhibitor of phosphodiesterase type 4 (PDE-4). Cipamfylline was tested in patients with a diagnosis of atopic dermatitis and in two human models of acute and chronic irritant contact dermatitis. The outcome of the study revealed that cipamfylline was more effective than vehicle in treating atopic dermatitis, but less effective than a group II steroid, hydrocortisone-17-butyrate both in the treatment of atopic dermatitis and irritant contact dermatitis. The absorption of cipamfylline and the subsequent systemic exposure might be the reason why further clinical studies with higher doses of cipamfylline have not been published.

Linoleyl methane sulfonate, a selective lipid-based vehicle, is utilized in drug delivery systems [1].

BGTC, a non-amino acid cationic lipid, serves as a vehicle for nucleic acid delivery [1].

18:1 PEG-PE is a PEGylated phospholipid functional end group for liposome synthesis, commonly used in the structural design of conjugated polymer nanoparticles.

Penetratin-Arg is an antimicrobial agent used as a drug delivery vehicle [1].

INX-SM-6, a chemical compound, serves as a targeted delivery vehicle for anti-inflammatory agents and has shown efficacy in suppressing LPS-induced IL-1β production in human PBMCs [1].

Nab-Paclitaxel is an albumin-bound formulation of Paclitaxel nanoparticles known for its enhanced response rates and tolerability. Leveraging albumin as a delivery vehicle, this compound achieves a favorable pharmacokinetic (PK) profile [1] [2].

A12-I20-2DC18, an ionizable cationic lipid, serves as an effective mRNA delivery vehicle [1].

Anti-FOLR1/FRA Antibody is a humanized monoclonal antibody targeting Folate Receptor alpha (FOLR1/FRA/FRα). FOLR1 is a Glycosylphosphatidylinositol (GPI)-anchored membrane protein responsible for mediating high-affinity folate uptake into cells. It is significantly overexpressed in various epithelial cancers, including ovarian, breast, and lung cancers, while showing restricted expression in normal tissues (except the kidney proximal tubules), making it an ideal tumor target. Anti-FOLR1/FRA Antibody specifically binds to FOLR1 on the tumor cell surface, blocking Lyn kinase-mediated signaling to inhibit cell proliferation, and inducing potent Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) to directly kill tumor cells. Furthermore, as the targeting moiety of Antibody-Drug Conjugates (ADCs), it serves as a critical vehicle for delivering cytotoxic payloads (e.g., DM4) into tumor cells.

Tividenofusp alfa (DNL-310) is a fusion protein created by combining IDS with Denali's proprietary Enzyme Transport Vehicle (ETV).

Anti-MUC17 Antibody is a humanized monoclonal antibody expressed in CHO cells targeting the transmembrane mucin MUC17 (also known as MUC3G). This product specifically recognizes the extracellular domain of MUC17. MUC17 is overexpressed in various gastrointestinal tumors, particularly gastric and colorectal cancers. The antibody binds to MUC17 on the cell surface, mediating antibody-dependent cellular cytotoxicity (ADCC), and serves as a vehicle for the targeted delivery of conjugated therapeutic payloads (as in ADC research) into tumor cells.

mPEG-CHO (MW 350) participates in the formation of three-dimensional porous scaffolds and acts as a delivery vehicle by carrying active substances. The -CHO functional group interacts with the -NH2 functional group of the chitosan chain to form a glutaraldehyde-type adduct, functionalizing mPEG. This functionalization and cross-linking can affect the rigidity of the delivery system, enabling the cross-linked conjugated system to have a slow-release function.